Communiqués Exelixis, Inc.

Actions

EXEL

US30161Q1040

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 26/06/2026 Varia. 5j. Varia. 1 janv.
54,77 USD +2,89% Graphique intraday de Exelixis, Inc. +5,51% +24,96%

Communiqués

22/06 Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer BU
30/05 Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026 BU
27/05 Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June BU
21/05 Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types BU
19/05 Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer BU
11/05 Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May 2026 AQ
07/05 Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May BU
06/05 Exelixis : Quarterly Report for Quarter Ending April 3, 2026 (Form 10-Q) PU
06/05 Exelixis : 260505 Exelixis Q1 2026 Earnings Slides With Appendix PU
05/05 Exelixis: Q1 Earnings Snapshot AQ
05/05 Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update BU
21/04 Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026 BU
24/02 Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March BU
10/02 Exelixis : 260210 Exelixis Q4 & FY25 Earnings Presentation With Appendix PU
10/02 Exelixis : Annual Report for Fiscal Year Ending January 2, 2025 (Form 10-K) PU
10/02 Exelixis: Q4 Earnings Snapshot AQ
10/02 Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update BU
02/02 Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer BU
27/01 Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026 BU
13/01 Exelixis : 260112 Exelixis JP Morgan 2026 Presentation PU
11/01 Exelixis : Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 PU
11/01 Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 BU
07/01 Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer BU
06/01 Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 BU
10/12 Exelixis : 251210 Exelixis 2025 R&D Day Presentation PU
Aucun résultat pour cette recherche